申请人:Astra AB
公开号:US05605916A1
公开(公告)日:1997-02-25
There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano; R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl; R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ; R.sub.3 represents hydrogen or C1 to 6 alkyl; in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl; or a pharmaceutically acceptable salt thereof. Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.
提供了一种治疗神经系统疾病(如癫痫、中风和脑缺血)的方法,其中包括给予化合物I的治疗:##STR1##其中,Ar.sub.1和Ar.sub.2可以相同或不同,独立地表示苯基或被氨基、硝基、卤素、羟基、C1到6烷氧基、C1到6烷基或氰基等取代的苯基;R.sub.1表示氢、C1到6烷基、C1到6烷氧基羰基;R.sub.2表示氢或COCH.sub.2 NH.sub.2;R.sub.3表示氢或C1到6烷基;此外,当R.sub.2表示氢时,Ar.sub.1和Ar.sub.2中的任意一个或两个也可以表示2-、3-或4-吡啶基,R.sub.1也可以表示三卤甲基;或其药学上可接受的盐。其中,化合物I中的一些是新型化合物,同时也提供这些新型化合物的制药组合物。